Abstract
The intravenous use of positive inotropic agents, such as sympathomimetics and phosphodiesterase inhibitors, in heart failure is limited by pro-arrhythmic and positive chronotropic effects. Chronic use of these agents, while eliciting an improvement in the quality of life of patients with advanced heart failure, has been abandoned because of marked increase in mortality when compared to placebo. Nevertheless, patients with advanced heart failure can benefit from long-term positive inotropic support if the therapy can be delivered ‘on demand’ and in a manner that is both safe and effective. In this review, we will examine the use of a novel, non-stimulatory electrical signal that can acutely modulate left ventricular (LV) contractility in dogs with chronic heart failure in such a way as to elicit a positive inotropic support. Cardiac contractility modulation (CCM) with the Impulse Dynamic™ signal was examined in dogs with chronic heart failure produced by intracoronary microembolizations. Delivery of the CCM signal from a lead placed in the great coronary vein for periods up to 10 minutes resulted in significant improvements in cardiac output, LV peak+dP/dt, LV fractional area of shortening and LV ejection fraction measured angiographically. Discontinuation of the signal resulted in a return of all functional parameters to baseline values. In cardiomyocytes isolated from dogs with chronic heart failure, application of the CCM signal resulted in improved shortening, rate of change of shortening and rate of change of relengthening suggesting that CCM application is associated with intrinsic improvement of cardiomyocyte function. The improvement in isolated cardiomyocyte function after application of the CCM signal was accompanied by an increase in the peak and integral of the Ca2+ transient suggesting modulation of calcium cycling by CCM application. In a limited number of normal dogs, intermittent chronic delivery of the CCM signal for up to 7 days showed chronic maintenance of LV functional improvement. In conclusion, pre-clinical results to date with the Impulse Dynamics CCM signal indicate that this non-pharmacologic therapeutic modality can provide short-term positive inotropic support to the failing heart and as such, may be a useful adjunct in the treatment of advanced heart failure. Additional, long-term studies in dogs with heart failure are needed to establish the safety and efficacy of this therapeutic modality for the chronic treatment of this disease syndrome.
Similar content being viewed by others
References
Packer M. Vasodilator and inotropic drugs for the treatment of chronic heart failure: Distinguishing hype from hope. J Am Coll Cardiol 1988;12:1299–1317.
Rahimtoola SH. The pharmacologic treatment of chronic congestive heart failure. Circulation 1989; 80:693–699.
Erlemeier H-H, Kupper W, Bleifeld W. Intermittent infusion of dobutamine in the therapy of severe congestive heart failure-long-term effects and the lack of tolerance. Cardiovasc Drugs Ther 1992; 6:391–398.
Chatterjee K. Phosphodiesterase inhibitors: Alterations in systemic and coronary hemodynamics. Basic Res Cardiol 1989;84 (suppl 1):213–224.
Kanayama H, Ban M, Ogawa K, Satake T. Myocardial concentration of norepinephrine and cyclic AMP in ventricular fibrillation during acute myocardial ischemia. J Cardiovasc Pharmacol 1982;4:1018–1023.
Lubbe WF, Podquweit T. Opie LH. Potential arrhythmogenic role of cyclic adenosine monophosphate (AMP) and cytosolic calcium overload: Implications for prophylactic effects of beta-blockers in myocardial infarction and proarrhythmic effects of phosphodiesterase inhibitors. J Am Coll Cardiol 1992;19: 1622–1633.
Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Electrophysiologic and proarrhythmic effects of intravenous inotropic agents. Prog Cardiovasc Dis 1995; 38:167–180.
Tisdale JE, Patel R, Webb CR, Borzak S, Zarowitz BJ. Proarrhythmic effects of intravenous vasopressors. Ann of Pharmacotherapy 1995;29:269–281.
Baumgart D, Ehring T. Krajcar M. Skyschally A, Heusch G. Characterization of the inotropic and arrhythmogenic action of the sodium channel activator BDF 9148: A comparison to its S-enantiomer BDF 9196, to its congener DPI 201±106, to norepinephrine, and to ouabain. Basic Res Cardiol 1994;89:61–79.
Raap A, Mest H-J, Stenzel W. Schloos J, Blechacz W. Investigation of the mechanism of the positive inotropic action of BDF 9148; comparison with DPI 201–106 and the enantiomers. J Cardiovasc Pharmacol 1997; 29:164–173.
Steinberg MI, McCall E, Mest H-J, Raap A. Wright T. Cardiac sodium channels as targets for new inotropic agents. Heart Failure Rev 1998;2:173–193.
Buggisch D, Isenberg G, Ravens U, Scholtysik GJ. The role of sodium channels in the effect of the cardiotonic compound DPI 201–106 on contractility and membrane potentials in isolated mammalian heart preparation. Eur J Pharmacol 1985;118: 303–311.
Bers DM. Excitation-Contraction Coupling and Cardiac Contractile Force. Kluwer Academic Press, Dordrecht, The Netherlands, 1991.
Raap A, Armah B, Hofferber E, Stenzel W, Schloos J, Blechacz W. BDF 9148: Comparison of action potential duration in vitro and prolongation of Q-T interval in anesthetized dogs (time course study) (Abstract). Naunyn-Schmiedebergs Arch Pharmacol 1991; 344:R85.
Rüegg PC, Nüesch E. The effect of a new inotropic agent, DPI 201–106, on systolic time intervals and the electrocardiogram in healthy subjects. Br J Clin Pharmacol 1987;24:453–458.
Algra A, Tijssen GJP, Roelandt JRTC, Pool J, Lubsen J. QTc prolongation measured by standard 12-lead electrocardiography is an independent risk factor for sudden death due to cardiac arrest. Circulation 1991; 83:1888–1894.
Cooper, MW. Postextrasystolic potentiation. Do we really know what it means and how to use it? Circulation 1993;88:2962–2971.
King, AJ, Taylor, DE. The inotropic action of paired pulse stimulation in the normal and failing heart: An experimental study. Cardiovasc Res 1968;2:122–129.
Hoffman BF, Artelstone HJ, Scherlag BJ, Cranefield Pf. Effects of postextrasystolic potentiation on normal and failing hearts. Bull N Y Acad Med 1965;41:498–534.
Sabbah HN, Mika Y, Aviv R, Haddad W, Darvish N, Ben-Haim SA, Chaudhry PA, Mishima T, Goldstein S. Delivery of non-excitatory contractility-modulation electric signals improve left ventricular performance in dogs with heart failure (Abstract). Circulation 1999;100:1–122.
Sabbah HN, Stein PD, Kono T, Gheorghiade M, Levine TB, Jafri S, Hawkins ET, Goldstein S. A canine model of chronic heart failure produced by multiple sequential coronary microembolizations. Am. J Physiol 1991;260:H1379-H1384.
Sabbah HN, Shimoyama H. Kono T, Gupta RS, Sharov VG, Scicli G, Levine TB, Goldstein S. Effects of longterm monotherapy with enalapril, metoprolol and digoxin on the progression of left ventricular dysfunction and dilation in dogs with reduced ejection fraction. Circulation 1994;89:2852–2859.
Tanimura M, Mishima T, Steinberg MI, Borzak S, Goldstein S, Sabbah HN: Hemodynamic effects of a novel sodium channel activator in dogs with chronic heart failure. Cardiovasc Drugs and Therapy, 2000; 14:77–82.
Lue WM, Boyden PA. Abnormal electrical properties of myocytes from chronically infarcted canine heart. Alterations in Vmax and the transient outward current. Circulation 1992;85:1175–1188.
Maltsev VA, Sabbah HN, Tanimura M, Lesch M, Goldstein S, Undrovinas AI. Relationship between action potential, contraction-relaxation and intracellular Ca2+ transient in cardiomyocytes of dogs with chronic heart failure. Cell Mol Life Sciences 1998;54:597–605. Electrical Modulation of Cardiac Contractility 53
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Sabbah, H.N., Haddad, W., Mika, Y. et al. Cardiac Contractility Modulation With the Impulse Dynamics Signal: Studies in Dogs With Chronic Heart Failure. Heart Fail Rev 6, 45–53 (2001). https://doi.org/10.1023/A:1009855208097
Issue Date:
DOI: https://doi.org/10.1023/A:1009855208097